Results 1 to 10 of about 24,646 (191)

Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux

Journal of Thrombosis and Haemostasis, 2003
Background: Fondaparinux is a synthetic pentasaccharide, which selectively inhibits coagulation factor (F) Xa, and is registered for prevention of venous thromboembolism following hip fracture, hip replacement, and knee replacement surgery.
Ton Lisman, J Adelmeijer, Joost C M Meijers   +2 more
exaly   +2 more sources

Total Synthesis of Anticoagulant Pentasaccharide Fondaparinux

ChemMedChem, 2014
Tiehai Li, Jie Shen, Peng George Wang
exaly  

Efficient and practical synthesis of Fondaparinux

Bioorganic and Medicinal Chemistry Letters, 2017
Yili Ding, Bingyun Wang
exaly  

Fondaparinux

2006
openaire   +1 more source

Reversal of the inhibitory effect of Fondaparinux on Thrombin generation by rFVIIa, aCCP and PCC

Thrombosis Research, 2009
C Negrier, Yesim Dargaud
exaly  

FONDAPARINUX

2010
openaire   +1 more source

Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients

International Orthopaedics, 2007
Takeshi Fuji, Satoru Fujita, Fujita Satoru   +2 more
exaly  

Development and in vivo bioavailability study of an oral fondaparinux delivery system

European Journal of Pharmaceutical Sciences, 2010
G Klima, Andreas Bernkop-Schnürch
exaly  

Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial

Lancet, The, 2002
Kenneth A Bauer, Bengt I Eriksson, Michael R Lassen   +2 more
exaly  

Fondaparinux Sódico

2022
openaire   +1 more source